

Immune monitoring in pancreatic cancer

Gepubliceerd: 20-12-2016 Laatste bijgewerkt: 19-03-2025

analysis of the systemic (blood) and local (tumor tissue) immune parameters in patients with pancreatic cancer and during conventional therapies could reveal new insights in the interplay of these treatment modalities with the immune system and...

Ethische beoordeling	Positief advies
Status	Werving gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON27380

Bron

Nationaal Trial Register

Aandoening

pancreatic cancer
alvleesklierkanker

Ondersteuning

Primaire sponsor: Foundation for Liver and Gastrointestinal Research (SLO)

Overige ondersteuning: Foundation for Liver and Gastrointestinal Research (SLO)

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

- To determine the baseline immune signature in pancreatic cancer patients.

Toelichting onderzoek

Achtergrond van het onderzoek

Patients diagnosed with pancreatic cancer have a poor survival. There is a strong need for new therapeutic approaches. The presence of pancreatic cancer is known to affect the functionality of the immune system and furthermore chemotherapy (CTx) and (chemo)radiotherapy (CRTx) can subvert immunosuppressive mechanisms, or elicit immune responses by immunogenic cell death of cancer cells. In depth analysis of the systemic (blood) and local (tumor tissue) immune parameters in patients with pancreatic cancer and during conventional therapies could reveal new insights in the interplay of these treatment modalities with the immune system and provide a basis/rationale for new (immuno)therapeutic approaches and combination therapies, e.g. including immune checkpoint blockade, adoptive immune therapies, Toll like receptors agonist and interferons in the current standard of care treatments.

Doel van het onderzoek

analysis of the systemic (blood) and local (tumor tissue) immune parameters in patients with pancreatic cancer and during conventional therapies could reveal new insights in the interplay of these treatment modalities with the immune system and provide a basis/rationale for new (immuno)therapeutic approaches and combination therapies.

Onderzoeksopzet

In general we will obtain a baseline sample from every patient (e.g. before surgery or before start of treatment) followed by several samples during their treatment course based on start of therapy and follow-up after each cycle of CTx and/or RTx (maximized at 11 timepoint in total).

Onderzoeksproduct en/of interventie

Blood collection

Contactpersonen

Publiek

's-Gravendijkwal 230
C.H.J. van Eijck
Surgery department Erasmus MC
Rotterdam 3000 CA

The Netherlands
+31 10 703 3854

Wetenschappelijk

's-Gravendijkwal 230
C.H.J. van Eijck
Surgery department Erasmus MC
Rotterdam 3000 CA
The Netherlands
+31 10 703 3854

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

- Age $\geq$ 18 years
- Diagnosed with resectable or borderline resectable pancreatic cancer, locally advanced pancreatic cancer or metastasized pancreatic cancer
- Planned treatment with either of the currently available standard of care treatments for pancreatic cancer (e.g. surgery, gemcitabine, FOLFIRINOX and/or radiotherapy)
- Signed informed consent

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

- Unable to draw blood for study purposes
- Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	N.v.t. / één studie arm
Blinding:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

Deelname

Nederland	
Status:	Werving gestart
(Verwachte) startdatum:	01-10-2016
Aantal proefpersonen:	200
Type:	Verwachte startdatum

Ethische beoordeling

Positief advies	
Datum:	20-12-2016
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 45549
Bron: ToetsingOnline
Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL6173

Register

NTR-old

CCMO

OMON

ID

NTR6320

NL59131.078.16

NL-OMON45549

Resultaten